Key Ideas

A single case of delayed neutropenia in a patient on sacituzumab govitecan exposed two compounding risk factors: unrecognized intermediate UGT1A1 metabolizer status and a weight-based dose-rounding policy that quietly delivered a 20% dose increase when only 10% was intended. Because antibody-drug conjugates are dosed per kilogram rather than by body surface area, routine weight-based rounding can produce dose changes far larger than clinicians expect.

A Case That Looked Routine Until It Wasn't

A woman in her late fifties with triple-negative, node-positive invasive ductal carcinoma of the right breast completed neoadjuvant chemotherapy, underwent bilateral mastectomy, and subsequently developed brain metastases. She was started on sacituzumab govitecan at the standard dose of 10 mg/kg on days 1 and 8 of a 21-day cycle and tolerated therapy well for nine cycles. Over that period her weight increased gradually, and per institutional policy, once cumulative weight change exceeded 10% from the initial dosing weight, the treatment plan was updated accordingly.

Following that adjustment, the patient developed neutropenia. Standard management, a one-week hold followed by resumption with prophylactic growth factor support on day 9 of each cycle, allowed her to continue therapy for ten more cycles before eventual progression. Comprehensive genomic testing performed at progression incidentally revealed that the patient was a UGT1A1 intermediate metabolizer, a finding that had been present the entire time but was never assessed before treatment began.

UGT1A1 Status Alone Did Not Explain the Neutropenia

Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate carrying an SN-38 payload, the same active metabolite produced by irinotecan. SN-38 is inactivated through glucuronidation by UGT1A1, so patients with reduced UGT1A1 activity, most notably those homozygous for the UGT1A1*28 allele, are at increased risk of neutropenia, febrile neutropenia, and anemia. The manufacturer's labeling flags this risk and recommends close monitoring in patients with known reduced UGT1A1 activity, but it offers no guidance on preemptive genotype testing, a gap reflected in current practice: this patient's case was the only one identified in a review specifically because UGT1A1 testing is not performed routinely before treatment initiation.

Critically, published data suggest that intermediate metabolizers (heterozygous for the 28 allele) experience rates of severe neutropenia similar to wild-type patients, both substantially lower than the rates seen in patients homozygous for the reduced-function allele. That distinction mattered here: the patient's intermediate status alone likely would not have driven her to manage differently than any other patient at baseline. The homozygous genotype, associated with clearly elevated rates of neutropenia, febrile neutropenia, and anemia along with earlier onset, is the group where testing carries the most actionable weight. Reduced-function alleles are not rare: an estimated 40% to 50% of patients carry the intermediate metabolizer genotype, and up to 20% of patients, particularly in Black populations, may be homozygous and severely deficient.

Because the neutropenia in this case occurred ten cycles into treatment, well after any expected early pharmacogenomic signal, and coincided precisely with the dose adjustment, UGT1A1 status alone was an unsatisfying explanation. A closer look at the dosing mechanics revealed the more likely culprit.

The Dose-Rounding Trap

Institutional policy rounds antibody-drug conjugate doses to the nearest available vial size when the calculated dose falls within 10% of the ordered dose. In this case, the patient's original weight of 62 kg had been rounded down to a 600 mg total dose. When her weight increased to 68 kg, triggering the planned dose update, the recalculated dose rounded up to 720 mg. The intended adjustment was a 10% dose increase; the actual, administered increase was 20%, purely as an artifact of where each weight fell relative to available vial sizes.

This is not a hypothetical concern specific to one drug. Because antibody-drug conjugates are dosed per kilogram rather than by body surface area, they are inherently more sensitive to weight-based rounding than BSA-dosed chemotherapy. A 10% intended dose change can translate to an actual delivered dose change of 20% to 33%, depending on the specific agent and the patient's body size relative to available vial increments, in either direction: a patient losing weight during a comparable rounding scenario could be significantly underdosed relative to the intended reduction.

Practical Takeaways for Dose Changes

When toxicity develops around the time of any dose adjustment, reviewing the actual administered dose and mg/kg received, rather than only the intended percentage change documented in the chart, is essential. This patient followed every rule of a well-designed weight-based rounding policy and institutional informatics system, and still experienced a significantly larger dose change than intended. Electronic health record systems do not currently flag this discrepancy by default; one health system informatics team has been asked to consider building an alert that compares intended dose modification against the dose the rounding rules actually produce, since without it, a clinician documenting a 20% reduction in the record may in practice be delivering no change at all, or vice versa. Until systems catch this automatically, manual verification of administered mg/kg against intended mg/kg remains the most reliable safeguard, particularly for any patient whose weight is trending in either direction.

For Patients

If you are receiving an antibody-drug conjugate, a newer class of cancer treatment that combines a targeted antibody with a chemotherapy payload, your dose is likely calculated based on your body weight rather than a fixed amount. As your weight changes over the course of treatment, your care team may adjust your dose, and because these medications are typically available only in certain preset amounts, rounding to the nearest available amount can sometimes result in a bigger or smaller change than intended.

This is not a reason for alarm, but it is a reason to ask questions. If you experience a new or worsening side effect, such as unusual fatigue, fever, or signs of infection, around the time your dose was adjusted for a weight change, let your care team know specifically when the change occurred. It may also be worth asking whether genetic testing for how your body processes certain chemotherapy drugs (a gene called UGT1A1) has been discussed, particularly if you experience early or unusually severe side effects, since some antibody-drug conjugates carry a labeled warning about this.

Key Takeaways

  • Sacituzumab govitecan's SN-38 payload is inactivated via UGT1A1, and patients homozygous for the UGT1A1*28 allele carry a labeled risk of increased neutropenia, febrile neutropenia, and anemia; preemptive genotype testing is not currently standard practice.

  • Intermediate (heterozygous) UGT1A1 metabolizer status appears to carry a risk profile similar to wild-type patients, distinct from the substantially higher risk seen in homozygous patients.

  • Weight-based rounding to available vial sizes can convert an intended 10% dose adjustment into an actual 20% to 33% change in delivered dose, in either direction.

  • Because antibody-drug conjugates are dosed per kilogram rather than by body surface area, they are more susceptible to this rounding effect than traditional BSA-dosed chemotherapy.

  • Reviewing actual administered mg/kg, not just the intended percentage change documented in the medical record, is currently the most reliable way to catch this discrepancy, since electronic health record systems do not yet flag it automatically.

References

  1. Trodelvy (sacituzumab govitecan-hziy) prescribing information. Gilead Sciences, Inc.

  2. Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human trophoblast cell-surface antigen 2 (Trop-2) expression. J Clin Oncol. 2024.

  3. Marmé F, et al. UGT1A1 genotype and safety of sacituzumab govitecan in patients with HR-positive, HER2-negative metastatic breast cancer.

  4. Dello Russo C, Asiimwe I, et al. UGT1A1 and sacituzumab govitecan toxicity: a systematic review and meta-analysis. Clin Pharmacol Ther. 2025.